|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Department of Adult Oncology and the
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute;
Department of Medicine, Harvard Medical School; and the Department of
Medicine, Brigham and Women's Hospital, Boston, MA.
CD40 engagement is the major signal that induces B cells to
efficiently present antigen to T cells. We previously demonstrated that
human peripheral blood-derived CD40-activated B cells (CD40-B cells)
function as antigen-presenting cells (APCs). Here, we have established
a culture system to generate these APCs under clinically applicable
conditions using guanylic acid-grade soluble trimeric CD40
ligand. To monitor APC function and antigen loading for these cells,
simple and efficient quality control assays have been developed. Using
this approach, we demonstrate that CD40-B cells from healthy donors
and cancer patients are fully functional and equally expanded in
long-term cultures. These B cells boost robust memory T-cell responses,
but more importantly, they also prime naive T-cell responses against
neoantigens ex vivo. CD40-B cells overcome current obstacles,
such as the difficulty of isolation, generation, and long-term
expansion observed with other APCs. Therefore, they are an excellent
source of professional APCs for immune assessment, antigen
discovery, and antigen-specific immunotherapy.
(Blood. 2002;99:3319-3325) Highly efficient antigen presentation by
professional antigen-presenting cells (APCs) is a requisite for the
development of T-cell-mediated immunity in vitro and in
vivo.1,2 Increasing evidence supports the
hypothesis that not all APCs have the same capacity to induce and
promote an immune response. For example, only dendritic cells
(DCs) have been shown to prime naive T cells and to induce memory T
cells to become effectors. For these reasons, many investigators
attempting to induce immunity to viral3,4 or tumor
antigens5-7 have focused their attention on DCs. In these fields, DCs have been used as cellular adjuvants to present antigen in vivo,8,9 as APCs in vitro to determine
immunocompetence, and, finally, in experiments attempting to
define immunogenic peptides from viral,10
autoimmune,11 and tumor antigens.12-14
Although highly efficient in their capacity to induce T-cell immunity,
DCs have several significant drawbacks. First, they are relatively rare
in peripheral blood and are therefore usually isolated from
apheresis8 or marrow sources.15 Second, DCs are not homogeneous but represent several populations of functionally disparate cell types,2 including tolerogenic
DCs.16 Third, it is difficult to expand DCs ex vivo
from non-stem cell sources without significant in vivo expansion with
cytokines.17 Finally, all of the above approaches are
laborious, expensive, and therefore presently restricted in their
clinical applicability.
We postulated that it would be advantageous to extend the sources of
APCs for antigen discovery, immune assessment, vaccination, and ex
vivo T-cell expansion. Ideally, biological characteristics would
include T-cell priming and highly efficient presentation of antigen.
Generation and expansion should be simple and possible from small
amounts of non-stem cell sources without the need to treat donors or
patients with biologics or chemotherapeutics prior to cell
collection.18,19 The APCs should be easily quality controlled, and their production should be based on the use of recombinant growth factors without the need for xenogeneic
cells20 or gene-transfer technology.21 We have
recently used CD40-activated B cells (CD40-B cells) as APCs for the ex
vivo generation of tyrosinase-specific T cells.22
Interactions between CD40 ligand (CD40L) on T cells and CD40 on
APCs have been shown to be crucial for the induction of cytotoxic
T-lymphocyte (CTL) immunity.23-25 Our earlier experiments using CD40-B cells to stimulate CTLs did not address whether CD40-B cells can prime T-cell responses since one cannot exclude the possibility that a pre-exposed and expanded tyrosinase-specific T-cell
pool exists even in healthy individuals. Furthermore, the system was
not clinically applicable owing to allogeneic and xenogeneic components, such as pooled human AB serum and human
CD40L-transfected murine fibroblasts (tCD40L). Here, we demonstrate
that CD40-B cells boost CTL responses to recall antigens, break
ignorance to tumor antigens, and prime T-cell responses to viral
neoantigens. We also describe the generation and expansion of CD40-B
cells from healthy individuals and cancer patients under clinically applicable conditions. Furthermore, we developed protocols to quality-control antigen-loading and APC function that help define rigorous clinical standards for CD40-B cells as APCs.
Donors and cell lines
The following tumor cell lines were used for cytotoxicity analysis:
U266, HS-Sultan, Malme-3M,26 SK-MEL-2 (ATCC, Manassas, VA), and U2OS.27 COS cells stably expressing
A*0201 were transiently transfected with pcDNA1.1amp
(Invitrogen, Carlsbad, CA) containing enhanced green fluorescent
protein (Clontech, Palo Alto, CA) and a human immunodeficiency virus
(HIV) reverse transcriptase (RT)-pol fusion minigene that
included the RTpol476 epitope by means of Lipofectamine Plus (Life
Technologies, Rockville, MD).
The CD40L system
Dendritic cells DCs were generated as previously described.22 Briefly, monocyte-enriched fractions were obtained from PBMCs by rosetting over sheep red blood cells and subsequently cultured for 6 to 8 days with 50 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) (Genzyme, Cambridge, MA) and 10 ng/mL IL-4 in IMDM supplemented with 2% human AB serum, 2 mM glutamine, and 15 µg/mL gentamicin. GM-CSF and IL-4 were replenished on day 4 of culture. Starting on day 6, DCs were matured for 48 hours with the use of 30 ng/mL tumor necrosis factor (TNF)- (Genzyme) or 2 µg/mL
sCD40L with or without 20 ng/mL interferon [IFN]-
Genzyme).30,31
Absolute number and density of cell surface molecules Dual-color fluorescence-activated cell sorter analysis was performed with monoclonal antibodies to CD19 (Beckman Coulter), major histocompatibility complex (MHC) class I and class II, CD58, and CD80 (Pharmingen).22 Quantitative determination of cell surface molecules was performed according to the manufacturer's recommendations by means of DAKO Qifikit (Dako). The antigen quantity is expressed in antigenic binding sites (ABSs). To determine the density of ABSs, we assumed that cells in suspension had a round shape. Using a Coulter Counter Z2, we determined the mean cellular volume of B-cell and DC populations and calculated the cell surface area as A = 4.83 × V2/3, where A stands for area and V for volume. This allows us to calculate the density as DABS = ABS/A, where D stands for density.Peptides Peptides were obtained from Sigma Genosys (The Woodlands, Texas). For the MHC class I experiments, an HLA-A*0201-binding peptide (Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val) (FLPSDFFPSV) derived from the hepatitis-B core protein was fluorescein isothiocyanate (FITC) conjugated at the internal cysteine (or C) residue after a single amino acid exchange at position 6 (FLPSDC(FITC)FPSV). The following peptides were used in binding studies and for the generation of peptide-specific CTLs: the native hepatitis-B core peptide F18 (FLPSDFFPSV)32; the pan-DR epitope peptide (PADRE) (Ala-Lys-Phe-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-Ala) (AKFVAAWTLKAAA)33; the I540 peptide of human telomerase reverse transcriptase (hTERT) (ILAKFLHWL, in which I is Ile and H is His)27; the RTpol476 peptide of HIV (ILKEPVHGV, in which E is Glu and G is Gly)34; the matrix protein 58 (MP58) peptide of influenza A (GILGFVFTL)35; E26-WT peptide (EAAGIGILTV) and the corresponding heteroclytic peptide E26-HT (ELAGIGILTV) of melanoma antigen recognized by T cells (MART-1).36Analysis of peptide pulsing To determine optimal pulsing conditions for exogenous peptide loading, APCs were harvested from culture, washed 3 times, and resuspended in serum-free IMDM at 1.25 × 106 cells per milliliter and seeded into 96-well plates (200 µL per well). Peptide concentration, incubation time and temperature, pH of culture medium, serum concentration, and concentration of 2
microglobulin (2-m) were varied. After incubation with
the FITC-conjugated reference peptide under different conditions, cells
were harvested, washed, and resuspended in PBS containing 0.1%
formaldehyde. Fluorescence analysis was performed immediately on a
Coulter EPICS XL flow cytometer. For competition assays, cells were
preincubated for 30 minutes at 4°C in a 5% CO2
atmosphere with increasing concentrations of the competitor peptide
(0.3 to 20 µg/mL) and 127.1/mM (1.5 µg/mL) 2-m. The
reference peptide was added at a concentration of 0.2 µg/mL for
150 minutes.
Ex vivo expansion of CTLs using CD40-activated B cells Long-term CD40-B-cell cultures (up to 50 days) were used as the source of APCs for repetitive stimulation of autologous T cells beginning at day 14 of B-cell culture. Long term-cultured CD40-B cells maintained their phenotype and efficiently presented antigen to T cells. HLA-A*0201+ CD40-B cells (or CD40L-matured DCs for control experiments) were incubated with peptide (up to 10 µg/mL), irradiated (32 Gy), and added to purified autologous CD8+ T cells (greater than 85%) at a T-cell-to-APC ratio of 4:1 in RPMI containing 10% human AB serum, glutamine, gentamicin, and IL-7 (10 ng/mL) (Endogen, Woburn, MA). On day 7, T-cell cultures were harvested, washed, and restimulated with fresh peptide-pulsed CD40-B cells and IL-7. This was repeated on days 14, 21, and 28. IL-2 (50 IU/mL) (Chiron, Emeryville, CA) was introduced into the cultures at day 8 and every 3 to 4 days thereafter.Cellular cytotoxicity assay Expanded autologous CD8+ T-cell lines were analyzed in a standard 4-hour 51Cr-release assay.27 Targets were labeled with 51Cr, and 5 × 103 labeled cells per well were plated with various concentrations of effector cells. The percentage of cytotoxicity was calculated as follows: [(cpm{experiment} spontaneous release)/(maximum cpm spontaneous release)] × 100%.
Tetramer analysis Recombinant tetrameric HLA-A2/peptide complexes with MP58, I540, RTpol476, MART-1HT, or human T-cell lymphoma virus (HTLV)-1 Tax 11 were synthesized essentially as described37 and conjugated to streptavidin ALEXA-488 or streptavidin-phycoerythrin (PE) (Molecular Probes, Eugene, OR). For staining, CTL lines were incubated with the tetramer for 15 minutes and with CD8-PE or CD8-PC5 (Coulter) for 20 minutes at room temperature. Dead cells were excluded by costaining with annexin V-FITC (R&D Systems).
CTL responses against viral and tumor antigens with CD40-B cells used as APCs CD40-B cells from healthy donors and cancer patients were used as the sole APCs to induce CTL responses to HLA-A*0201-restricted epitopes derived from the recall antigen influenza A MP58; the tumor antigens MART-1 (E26) and hTERT (I540); and the neoantigen RTpol (RTpol476) from HIV. By means of peptide-pulsed T2 cells, peptide specificity was demonstrated for all 4 antigens (Figure 1A). As expected for memory T-cell responses, CTLs specific for the influenza A-derived peptide MP58 were already highly cytotoxic after one stimulation, and cytolysis was generally higher than for the other CTL. Nevertheless, after 4 stimulations, CTLs specific for the tumor antigens MART-1 or hTERT showed maximum lysis (effector-to-target ratio of 30:1) of peptide-pulsed targets. Lysis of CTLs specific for the neoantigen RTpol was significant although in general lower than lysis of recall antigen-specific T cells. In addition CTLs specific for influenza A, MART-1, hTERT, and RTpol also produced IFN- after
peptide-specific activation as determined by enzyme-linked immunospot
(ELISPOT) analysis (data not shown).
MHC/peptide tetramer analysis was performed to assess expansion of peptide-specific CTLs in these cultures (Figure 1B). More than 40% of all CD8+ T cells in the expanded population were MP58-specific (day 18). With the use of autologous CD40L-matured monocyte-derived DCs as APCs,30,31control CTL cultures specific for MP58 (n = 6) did not show significant differences in T-cell expansion and function (data not shown). On day 25 of culture, 21.5% of CD8+ T cells stained with the specific MART-1 tetramer, and 16.8% of the CD8+ T cells stained with the hTERT tetramer. Expansion of RTpol-specific CTLs was significantly less and reached only 0.39% to 3.79% of all CD8+ CTLs after 25 days. For therapeutic use, it is essential to demonstrate that CTLs can
recognize endogenously processed antigen (Figure 1C). CTLs specific for
MART-1 lysed the HLA-A2+ MART-1+ melanoma cell
line MALME-3M but not the HLA-A2 Finally, we compared CD40-B cells with CD40-matured DCs as the priming APCs in this culture system (Figure 1A-C, RTpol panel, and Figure 1E). In 4 of 6 experiments comparing autologous CD40L-matured monocyte-derived DCs (6 CTL lines) and autologous CD40-B cells (6 CTL lines) as primary APCs, RTpol-specific CTLs were induced under both conditions. There was no significant difference in peptide-specific lysis (Figure 1A,E, upper panel); number of CTLs staining the RTpol476 MHC/peptide tetramer complex after expansion (Figure 1B,E, middle panel); or lysis of APCs endogenously expressing the RTpol476 epitope (Figure 1C,E, lower panel). Taken together, these data show that CD40-B cells from healthy donors and cancer patients reliably boost viral antigen-specific memory T cells, break T-cell ignorance to tumor antigens, and can also prime neoantigen specific T cells ex vivo. Clinical applicability of the CD40-B-cell system Simple and reliable generation and expansion of APCs from non-stem cell sources determines their clinical applicability. To address this issue, CD40-B cells from PBMCs of 8 cancer patients and 41 healthy individuals were generated by 8 investigators during a period of 18 months. In total, 56 cultures were performed. Three of these 56 cultures were discontinued owing to bacterial contamination. The 90% exact confidence interval for successful expansion was 87% to 99%. Figure 2A shows the total cell count over time in the 53 individual cultures with a culture period of at least 14 days. All cultures showed similar growth kinetics: there was a drop in cell number during the first 5 to 10 days, followed by a significant expansion during the remaining culture period. When the culture started with 108 PBMCs, the mean cell count of CD19+ B cells after 27 days of culture was 6.42 × 109 (range, 3.49 × 108 to 5.03 × 1010). When initial B-cell numbers in the cultures were normalized (11 healthy donors and 8 cancer patients), a continuous expansion of B cells over time was observed, leading to a mean increase of 2032-fold (range, 226- to 6226-fold increase) at day 27 (Figure 2B). There was no difference between cancer patients and healthy donors. CD40-B cells are completely dependent on CD40L and IL-4 since discontinuation of these 2 factors led to cell death by apoptosis in fewer than 4 days (data not shown).
For therapeutic use of CD40-B cells, it is desirable to avoid the use
of culture medium supplemented with pooled human AB serum. In 7 cancer
patients, we replaced the pooled serum (Figure 2B) with
autologous plasma (Figure 2C) and demonstrated no statistically significant difference of B-cell expansion, suggesting that plasma can
be used instead of pooled AB serum in this system. Replacing the
xenogeneic component (tCD40L) of the CD40-B-cell system with another
source of CD40L would significantly improve its clinical applicability.
We therefore tested GMP-grade human trimeric soluble CD40L
(sCD40L).28 In the presence of rhIL-4 and CsA, sCD40L induced a significant B-cell expansion (3 orders of magnitude), which
did not differ from that observed for B cells stimulated with tCD40L
(Figure 3). As expected,38
rhIL-4 was an important cofactor since B-cell expansion in cultures
with tCD40L or sCD40L alone did not expand over the whole culture
period and could not be replaced by other cytokines, including IL-6 or
TNF-
Determination of cell surface molecules as surrogates for APC function of CD40-B cells The generation of antigen-specific CTL lines using CD40-B cells cannot be routinely performed as an assay to control for efficient APC function of these cells, particularly in a clinical setting. Since sufficient expression of MHC, adhesion, and costimulatory molecules closely correlates with APC function,39,40 phenotypic analysis of these cell surface molecules was applied as a fast and reliable surrogate readout for APC function of CD40-B cells. For optimal comparison of different culture conditions and for comparison with other cells, the analysis was normalized for number of molecules (ABSs) and cell size. CD40-B cells were generated in the presence of rhIL-4, CsA, tCD40L, or sCD40L, and phenotypic analyses were performed between day 16 and 28. Since IFN- is known to increase the
expression of MHC molecules,41 the effect of IFN- was
also measured. Monocyte-derived mature and immature DCs were used as
positive controls. As shown in Figure 4A,
significant numbers of CD80 (6381 to 15 600 ABSs per cell); CD58
(17 213 to 59 987 ABSs per cell); MHC class I (17 260 to 106 916
ABSs per cell); and MHC class II molecules (294 130 to 1 016 785
ABSs per cell) were expressed on CD40-B cells. No statistically
significant difference between sCD40L and tCD40L was observed for these
4 surface molecules, and the addition of IFN- did not further
increase their expression. The absolute number of CD80, MHC class I,
and MHC class II reached that of immature and TNF--matured DCs;
only CD40L/IFN--matured DCs showed higher levels. Despite
significant expression of CD58 on CD40-B cells, DC controls showed a
consistently higher absolute expression.
After normalization for cell size, the density of CD58 and MHC class I
was in the same range for CD40-B cells and all control DCs. Expression
of CD80 and MHC class II molecules was denser on CD40-B cells than on
immature or TNF- Visualization and quantification of antigen delivery to CD40-B cells To use APCs therapeutically, it is critical to ensure and monitor efficient antigen delivery. To address this issue for CD40-B cells, we applied direct visualization of peptide loading using a fluorochrome-labeled HLA-A2-binding peptide derived from the hepatitis-B core protein (FITC-conjugated F18).42 HLA-A2+, but not HLA-A2 , CD40-B cells showed
significant fluorescence after peptide pulsing at concentrations lower
than 2 µg/mL (Figure 5A), whereas an
HLA-A2-independent increase in fluorescence was observed at
concentrations exceeding 2 µg/mL. Peptide-binding analysis using T2
cells revealed no significant difference in HLA-A2 binding between the
FITC-conjugated and the native F18 peptide (data not shown). Maximum
peptide loading, reaching approximately 10 000 molecules per cell, was
achieved at 0.2 µg/mL peptide in 30 minutes at 37°C in serum-free
medium without the necessity of 2-m. Control experiments
showed comparable peptide loading of DCs (approximately 12 000
molecules per cell for immature DCs, approximately 6000 molecules per
cell for mature DCs; data not shown). Optimized peptide-loading also
correlated with maximum cytolysis of peptide-loaded CD40-B cells by
peptide-specific CTL. A dose-dependent cytolysis of influenza A
MP58-pulsed CD40-B cells was determined at peptide concentrations
below 2 µg/mL, whereas higher concentrations did not lead to
increased cytotoxicity (data not shown).
For the application of CD40-B cells with other peptides, a competition assay was established with the use of the FITC-conjugated F18 peptide as a reference peptide. Using this assay, we demonstrated binding of 2 peptides with known high affinity for HLA-A2. The native F18 peptide and the I540 peptide from hTERT27 led to significant reduction of fluorescence with the addition of increasing concentrations of peptide (Figure 5B). In contrast, as expected, the HLA-DR-binding peptide PADRE33 did not compete with the FITC-conjugated F18 peptide for HLA-A2 binding. Owing to a significant loss of viability under these experimental conditions, DCs could not be used as controls. Taken together, CD40-B cells are efficiently loaded with peptide under
serum-free conditions without the need of
The CD40-B-cell system is an autologous system for efficiently expanding highly effective APCs without the use of xenogeneic fibroblasts,20 viral components such as Epstein-Barr virus,43 or gene-transfer technology.21 The value of CD40-activated B cells for antigen screening and immune assessment was demonstrated by ex vivo generation of antigen-specific CTLs to recall antigens (eg, influenza A), tumor antigens (eg, hTERT, MART-1), and neoantigens (eg, HIV RTpol in seronegative donors). Applicability of CD40-B cells for clinical use was established by successful replacement of allogeneic, pooled AB serum with autologous plasma and of xenogeneic CD40L transfectants with human GMP-grade soluble trimeric CD40L. The normalized analysis of important cell surface molecules is a simple method to ensure and control the quality of this cellular product as highly efficient APCs. Optimized delivery of peptide antigens, important for clinical applications of any cellular adjuvant, is demonstrated for CD40-B cells by direct visualization of peptide binding in a competition assay using fluorescence-labeled reference peptides. This system is suitable for clinical-grade large-scale expansion of highly efficient APCs in cancer patients. For an APC to be applicable to antigen discovery and as a cellular adjuvant for vaccination, it is critical to demonstrate that the APC not only boosts T-cell responses to recall antigen but also initiates T-cell responses to neoantigens. DCs are the only APCs that have been reported to prime T cells in vivo1 and in vitro.10,44,45 Priming of human T cells in vitro can be formally addressed only by induction of CTL responses against viral neoantigens in seronegative individuals. Here, we demonstrate that CD40-B cells not only boost T-cell responses to recall antigens such as influenza A but also stimulate T-cell responses to tumor antigens that are ignored (eg, hTERT; R.H.V. and J.L.S., unpublished results, June 2001) and stimulate naive T cells specific for neoantigens, such as RTpol from HIV. On the basis of current knowledge about the T-cell repertoire for HIV10,44,45 in healthy individuals, the successful ex vivo expansion of HIV-specific CTLs in seronegative healthy individuals strongly supports that the CD40-B-cell system can prime naive T cells ex vivo. For further evaluation, the CD40-B-cell system was applied to our tumor antigen discovery program. So far we have tested 14 potential candidate antigens and have been able to identify 23 immunogenic epitopes and 5 heteroclitic peptides using CD40-B cells as APCs (M.S.V.B.-B. and J.L.S., unpublished results, February 2001). Antigen delivery to APCs is critically important in the development of cellular vaccines, and so far there has been little attention to ensure efficient and reproducible antigen delivery in previous and ongoing trials.46 Fluorescein-labeled peptides have been used mainly to study peptide/MHC interactions on murine cell lines.47-49 We applied this simple technology to visualize peptide binding on primary APCs, such as CD40-B cells and DCs, and to optimize peptide-pulsing conditions. These experiments revealed that the amount of peptide loaded onto CD40-B cells under optimized conditions exceeds the amount of peptide necessary for T-cell activation.50 By using this technique in upcoming vaccine trials, we will be able to determine the impact of insufficient antigen delivery on vaccination efficiency. This technique is not restricted to the most common HLA types. As long as a high affinity-binding peptide is known for the HLA allele of interest, a competition assay using this peptide as a fluorescein-labeled competitor can be established for every patient. While CD40-B cells generated in coculture with CD40L transfectants are suitable for research purposes and immune assessment, it is preferable to use human GMP-grade soluble trimeric CD40L for therapeutic applications of CD40-B cells to avoid any potential danger from contact with xenogeneic culture components. In fact, cells such as CD40-B cells generated for therapeutic purposes by coculture with xenogeneic-transfected fibroblasts would fall under regulations established for xenotransplantation and gene therapy, thereby significantly limiting clinical applicability.51 This is probably one of the major disadvantages of artificial APCs,20,52-54 which have been suggested as an alternative to human professional APCs. Moreover, unlike DCs and CD40-B cells, artificial APCs lack other human molecules, including cell surface molecules, cytokines, and chemokines, that significantly contribute to the activation and expansion of T cells.55-58 CD40-B cells can be generated in great numbers and might therefore facilitate "dose escalation" of therapeutic vaccination. The beneficial effect of frequent vaccinations with significant numbers of cells in the tumor-bearing host has been clearly demonstrated by Ochsenbein et al.59 In this murine model, tumor regression of well-established tumors was achieved only when antigen-loaded APCs were applied repetitively over a period of 3 weeks. In contrast to DCs, B cells are normally not surveying subcutaneous tissue, and ex vivo-generated CD40-B cells might therefore be incapable of migration into draining lymph nodes. However, in mice, injected B cells are indeed capable of migrating to lymphoid organs even after subcutaneous injection.60 Taken together, CD40-B cells are a powerful source of APCs generated by simple and reliable technology that can be applied to antigen screening, immune assessment, vaccination approaches, and ex vivo T-cell expansion for adoptive therapy.
We thank J. Daley, M. Bedor, K. Hoar, D. Schnipper, and Y. Chen for excellent technical assistance and Dr D. Neuberg for statistical assistance.
Submitted December 20, 2000; accepted December 26, 2001.
Supported by the Deutsche Krebshilfe und Dr Mildred Scheel Stiftung (M.S.v.B.-B.); the Deutsche Forschungsgemeinschaft (B.M.); grant CI2 of the Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation (R.H.V.); the Sankyo Foundation of Life Science (N.H.); National Institutes of Health grants K08-CA-88444-01 (K.S.A.), K08-CA-87720-01 (M.O.B.), P01-CA-66996, and P01-CA-78378 (L.M.N.); a Special Fellowship of the Leukemia and Lymphoma Society (J.L.S.); and a Translational Research Award by the Leukemia and Lymphoma Society (J.L.S.).
R.H.V. and B.M. contributed equally to this study.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Joachim L. Schultze, Tumor Immunology Laboratory, Dept of Hematology/Oncology, University of Cologne, Joseph-Stelzmann St 9/Haus 16, 50924 Cologne, Germany; e-mail: joachim.schultze{at}medizin.uni-koelne.de.
1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296[CrossRef][Medline] [Order article via Infotrieve]. 2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252[CrossRef][Medline] [Order article via Infotrieve].
3.
Shimizu Y, Guidotti LG, Fowler P, Chisari FV.
Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.
J Immunol.
1998;161:4520-4529
4.
Schlienger K, Craighead N, Lee KP, Levine BL, June CH.
Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells.
Blood.
2000;96:3490-3498
5.
Nair S, Zhou F, Reddy R, Huang L, Rouse BT.
Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro.
J Exp Med.
1992;175:609-612
6.
Boczkowski D, Nair SK, Snyder D, Gilboa E.
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
J Exp Med.
1996;184:465-472
7.
Paglia P, Chiodoni C, Rodolfo M, Colombo MP.
Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
J Exp Med.
1996;183:317-322 8. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58[CrossRef][Medline] [Order article via Infotrieve]. 9. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332[CrossRef][Medline] [Order article via Infotrieve].
10.
Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F.
Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro.
Blood.
2000;96:1327-1333 11. Guery JC, Adorini L. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J Immunol. 1995;154:536-544[Abstract]. 12. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998;16:364-369[CrossRef][Medline] [Order article via Infotrieve].
13.
Brossart P, Heinrich KS, Stuhler G, et al.
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
Blood.
1999;93:4309-4317
14.
Chaux P, Luiten R, Demotte N, et al.
Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
J Immunol.
1999;163:2928-2936 15. Siena S, Di Nicola M, Bregni M, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol. 1995;23:1463-1471[Medline] [Order article via Infotrieve]. 16. Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol. 1996;157:1406-1414[Abstract]. 17. Ardeshna KM, Pizzey AR, Thomas NS, Orr S, Linch DC, Devereux S. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br J Haematol. 2000;108:817-824[CrossRef][Medline] [Order article via Infotrieve]. 18. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol. 1996;24:859-862[Medline] [Order article via Infotrieve].
19.
Brugger W, Brossart P, Scheding S, et al.
Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation.
Ann N Y Acad Sci.
1999;872:363-371 20. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol. 2000;18:405-409[CrossRef][Medline] [Order article via Infotrieve]. 21. Anderson WF. Human gene therapy. Nature. 1998;392:25-30[CrossRef][Medline] [Order article via Infotrieve]. 22. Schultze JL, Michalak S, Seamon MJ, et al. CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100:2757-2765[Medline] [Order article via Infotrieve]. 23. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474-478[CrossRef][Medline] [Order article via Infotrieve]. 24. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480[CrossRef][Medline] [Order article via Infotrieve]. 25. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483[CrossRef][Medline] [Order article via Infotrieve].
26.
Kawakami Y, Eliyahu S, Delgado CH, et al.
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
Proc Natl Acad Sci U S A.
1994;91:3515-3519 27. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673-679[CrossRef][Medline] [Order article via Infotrieve].
28.
Morris AE, Remmele RL Jr, Klinke R, Macduff BM, Fanslow WC, Armitage RJ.
Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154).
J Biol Chem.
1999;274:418-423
29.
Schultze JL, Cardoso AA, Freeman GJ, et al.
Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.
Proc Natl Acad Sci U S A.
1995;92:8200-8204
30.
Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G.
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.
J Exp Med.
1996;184:747-752
31.
Koch F, Stanzl U, Jennewein P, et al.
High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.
J Exp Med.
1996;184:741-746
32.
Bertoletti A, Chisari FV, Penna A, et al.
Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.
J Virol.
1993;67:2376-2380 33. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1:751-761[CrossRef][Medline] [Order article via Infotrieve].
|
Top
Abstract
Introduction
) and HLA-A2-binding control peptide
(
) (upper panel); percentage of CD8+
tetramer+ T cells (middle panel); and recognition of
endogenously processed peptide with the use of HLA-A2+
RTpol+ COS cells (
